Nanoenzyme-based sensors for the detection of anti-tumor drugs
- PMID: 39847110
- DOI: 10.1007/s00604-024-06822-2
Nanoenzyme-based sensors for the detection of anti-tumor drugs
Abstract
Natural enzymes are a class of biological catalysts that can catalyze a specific substrate. Although natural enzymes have catalytic activity, they are susceptible to the influence of external environment such as temperature, and storage requirements are more stringent. Since the first discovery of magnetic Fe3O4 nanoparticles with peroxidase-like activity in 2007, the research on nanoenzymes has entered a rapid development stage. Nanoenzymes synthesized by chemical methods not only have the catalytic activity of natural enzymes but also are more stable, easy to store, and convenient to prepare. Anthracyclines, as a commonly used anti-tumor chemotherapy drug, will produce many side effects such as myelosuppression and liver function damage after long-term use, which will affect its therapeutic effects. This paper reviews the characteristics, classification, and mechanisms of nanoenzymes. The detection of anti-tumor drugs, especially anthracycline drugs, using a nanoenzyme-based sensor was emphatically introduced. On this basis, the application of nanoenzyme-based sensors in the detection of anti-tumor drugs is prospected.
Keywords: Anthracyclines; Anti-tumor drugs; Colorimetric sensor; Electrochemical sensors; Fluorescent sensors; Nanoenzymes.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Conflict of interest statement
Declarations. Humans and animal rights and informed consent: This research did not involve human or animal samples. Conflict of interest: The authors declare no competing interests.
Similar articles
-
The peroxidase/catalase-like activities of MFe₂O₄ (M=Mg, Ni, Cu) MNPs and their application in colorimetric biosensing of glucose.Biosens Bioelectron. 2015 Jan 15;63:384-391. doi: 10.1016/j.bios.2014.07.048. Epub 2014 Jul 25. Biosens Bioelectron. 2015. PMID: 25127473
-
A peroxidase biomimetic system based on Fe3O4 nanoparticles in non-enzymatic sensors.Talanta. 2015 Aug 15;141:307-14. doi: 10.1016/j.talanta.2015.03.017. Epub 2015 Mar 20. Talanta. 2015. PMID: 25966419
-
Facile preparation of Fe3O4@Pt nanoparticles as peroxidase mimics for sensitive glucose detection by a paper-based colorimetric assay.R Soc Open Sci. 2022 Sep 28;9(9):220484. doi: 10.1098/rsos.220484. eCollection 2022 Sep. R Soc Open Sci. 2022. PMID: 36177202 Free PMC article.
-
Single-Atom-Based Nanoenzyme in Tissue Repair.ACS Nano. 2024 May 21;18(20):12639-12671. doi: 10.1021/acsnano.4c00308. Epub 2024 May 8. ACS Nano. 2024. PMID: 38718193 Review.
-
Chiral nanoenzymes: synthesis and applications.Mikrochim Acta. 2024 Nov 4;191(12):723. doi: 10.1007/s00604-024-06803-5. Mikrochim Acta. 2024. PMID: 39495306
Cited by
-
Herbal Medicine: Enhancing the Anticancer Potential of Natural Products in Hepatocellular Carcinoma Therapy Through Advanced Drug Delivery Systems.Pharmaceutics. 2025 May 20;17(5):673. doi: 10.3390/pharmaceutics17050673. Pharmaceutics. 2025. PMID: 40430962 Free PMC article. Review.
References
-
- Ibrahim A, El Baldi M, Mohammed S et al (2024) Cancer statistics in Yemen: incidence and mortality, in 2020. BMC Public Health 24(1):962. https://doi.org/10.1186/s12889-024-18207-4 - DOI - PubMed - PMC
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–49. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Coles CE, Earl H, Anderson BO et al (2024) The Lancet Breast Cancer Commission. Lancet. https://doi.org/10.1016/s0140-6736(24)00747-5
-
- James ND, Tannock I, N’Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683–722. https://doi.org/10.1016/s0140-6736(24)00651-2 - DOI - PubMed - PMC
-
- Samara P, Athanasopoulos M, Goulioumis A et al (2023) Malignant tumors of the external auditory canal: diagnosis, treatment, genetic landscape, biomarkers, and clinical outcome. Explor Target Antitumor Ther 4(5): 801–11. https://doi.org/10.37349/etat.2023.00169